Objective:
To evaluate the effects of complement inhibition therapy on geographic atrophy (GA) progression in patients with neovascular age-related macular degeneration (nAMD).
Key Findings:
- GA lesion growth rate decreased from 1.5 mm² to 0.8 mm² post-treatment.
- Complement inhibition did not increase CNV activity, with only 4 eyes showing new signs of CNV.
- Visual acuity remained stable over the 1-year follow-up period.
Interpretation:
Complement inhibition therapy effectively slows GA progression in patients with wet AMD without negatively impacting CNV activity.
Limitations:
- Retrospective design may introduce bias.
- Small sample size of 33 eyes limits generalizability.
Conclusion:
Complement inhibition is a viable treatment option for patients with GA and wet AMD, allowing for stable disease management.
This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.